Nasdaq

Lifecore Biomedical Signs 10-Year Commercial Manufacturing Agreement to Advance Novel Ophthalmic Therapeutic

Lifecore Biomedical, Inc. announced a new 10-year commercial manufacturing and supply agreement with one of its existing customers to support the development of a novel ophthalmic therapeutic. This ...
Seeking Alpha

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (LFCR) (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today ...
Seeking Alpha

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (LFCR) (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today ...
Nasdaq

Lifecore Biomedical Appoints Mark DaFonseca as Chief Commercial Officer to Drive Growth Strategy

Lifecore Biomedical has appointed Mark DaFonseca as its new chief commercial officer, bringing nearly 30 years of experience in drug development and over 15 years leading sales organizations in the ...
The National Law Review

Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise ...
The Business Journals

Cancer treatment company to open 1st commercial lab

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Miami startup raised ...